This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.







FIG.1



Replacement Sheet

FIG.2




FIG.3

4/16 untreated group saline administrated group MK administrated group

untreated group

saline administrated group

MK administrated group

Lane

1: cisplatin untreated

2: cisplatin

3: human MK 100 ng/ml

4: cisplatin + human MK 100 ng/ml

5: mouse MK 100 ng/ml

6: cisplatin + mouse MK 100 ng/ml

1 2 3 4 5 6

FIG.6




FIG.7

Filing Date: Aug. 15, 2003 Applicant: Ikematsu et al.





FIG.8



Sham-op group



saline administrated group



MK administrated group

X100




FIG.10





FIG.11






FIG.13




FIG.14




FIG.15




FIG.16